All In Biotech

Drug Trial Radar · NCT05118542

Effect of Hyperthyroidism and Its Treatment in Graves' Disease to Early Marker of Atherosclerosis

Effect of Hyperthyroidism and Its Treatment in Graves' Disease to Early Marker of Atherosclerosis: Review on the Pathway of Insulin Resistance, Lipid, Inflammation, and Endothelial Dysfunction to Pulse Wave Velocity and Carotid Intima-Media Thickness

Last checked: Nov 20, 2026Latest source record: Nov 12, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

36

Actual

Start

Jan 1, 2019

Primary completion

Jun 1, 2020

Study completion Aug 1, 2020

Sponsor

Lead sponsor
Universitas IndonesiaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 12, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

During July 2019 to August 2020, a single-blind clinical trial was done to 36 patients with Graves' disease. At the beginning of the study, subjects were accommodated into 2 groups, 17 into PTU groups and 19 into methimazole groups. There were 24 subjects who finished the study, 13 from PTU group and 11 from methimazole group. Blood serum was collected for HOMA-IR, LDL-R, NFĸB, sICAM-1, sVCAM-1 and sE-selectin examination. Meanwhile stiffness and thickness of carotid artery was measured using PWV and cIMT.

Conditions

  • Hyperthyroidism
  • Graves Disease
  • Atherosclerosis of Artery
  • Pathophysiology

Interventions

  • PropylthiouracilDrug

    PTU were given to participants with adjusted dosage according to patient clinical assessment at every visit by their own endocrinologist.

  • MethimazoleDrug

    methimazole were given to participants with adjusted dosage according to patient clinical assessment at every visit by their own endocrinologist.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pulse Wave VelocityTime frame: Change from Baseline to 3 month follow-up
  2. carotid intima media thicknessTime frame: Change from Baseline to 3 month follow-up

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Indonesia

    Jakarta Pusat, Jakarta Special Capital Region, Indonesia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.